Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function
Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...
PMLive1 天
Medscape at ACC 2025: From Taking the Pulse to Getting to the Heart of It
The Medscape team is back in Chicago for the much-anticipated ACC 2025 conference,  March 29-31, bringing an array of ...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac ...
Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...
The Cardiology Advisor1 天
FDA Approves Losartan Oral Suspension Arbli
The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until ...
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers ...
What's Going On With Scienture Shares Tuesday?
Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...
Healio7 天
Q&A: Novel drug may replace ‘watchful waiting’ approach to aortic stenosis care
A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...
Scienture announces U.S. FDA approval of NDA for SCN-102
Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...
Modern Ghana7 天
Beyond Medication: Integrative Therapies for Hypertrophic Cardiomyopathy
Imagine receiving a diagnosis that changes your life in an instant: hypertrophic cardiomyopathy, a heart condition that can strike without warning, claiming thousands of lives annually .
Renal & Urology News8 天
Study IDs Post-Transplant Anemia Contributors, Clarifies Role of ESAs
A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).
dvm3608 天
FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy
Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...
Heartlung Technologies Selected As A Finalist For ACC 2025 Innovation Pitch Challenge
HeartLung Technologies selected as a finalist and will compete at the ACC 2025 Innovation Pitch Challenge in Chicago. Marlon Montes HeartLung Corporation +1 310-510-6004 ... Visit us on social media: ...